» Articles » PMID: 26731012

National Lupus Hospitalization Trends Reveal Rising Rates of Herpes Zoster and Declines in Pneumocystis Pneumonia

Overview
Journal PLoS One
Date 2016 Jan 6
PMID 26731012
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Infection is a leading cause of morbidity and mortality in systemic lupus erythematosus (SLE). Therapeutic practices have evolved over the past 15 years, but effects on infectious complications of SLE are unknown. We evaluated trends in hospitalizations for severe and opportunistic infections in a population-based SLE study.

Methods: Data derive from the 2000 to 2011 United States National Inpatient Sample, including individuals who met a validated administrative definition of SLE. Primary outcomes were diagnoses of bacteremia, pneumonia, opportunistic fungal infection, herpes zoster, cytomegalovirus, or pneumocystis pneumonia (PCP). We used Poisson regression to determine whether infection rates were changing in SLE hospitalizations and used predictive marginals to generate annual adjusted rates of specific infections.

Results: We identified 361,337 SLE hospitalizations from 2000 to 2011 meeting study inclusion criteria. Compared to non-SLE hospitalizations, SLE patients were younger (51 vs. 62 years), predominantly female (89% vs. 54%), and more likely to be racial/ethnic minorities. SLE diagnosis was significantly associated with all measured severe and opportunistic infections. From 2000 to 2011, adjusted SLE hospitalization rates for herpes zoster increased more than non-SLE rates: 54 to 79 per 10,000 SLE hospitalizations compared with 24 to 29 per 10,000 non-SLE hospitalizations. Conversely, SLE hospitalizations for PCP disproportionately decreased: 5.1 to 2.5 per 10,000 SLE hospitalizations compared with 0.9 to 1.3 per 10,000 non-SLE hospitalizations.

Conclusions: Among patients with SLE, herpes zoster hospitalizations are rising while PCP hospitalizations are declining. These trends likely reflect evolving SLE treatment strategies. Further research is needed to identify patients at greatest risk for infectious complications.

Citing Articles

Rates of Pneumocystis jirovecii pneumonia and prophylaxis prescribing patterns in a large electronic health record cohort of patients with systemic lupus erythematosus.

Boone B, Lazaroff S, Wheless L, Wolfe R, Barnado A Semin Arthritis Rheum. 2022; 57:152106.

PMID: 36279805 PMC: 9937021. DOI: 10.1016/j.semarthrit.2022.152106.


Avoidable Acute Care Use for Vaccine-Preventable Illnesses Among Medicaid Beneficiaries With Lupus.

Feldman C, Xu C, Costenbader K Arthritis Care Res (Hoboken). 2021; 73(9):1236-1242.

PMID: 33949140 PMC: 9357464. DOI: 10.1002/acr.24628.


Estimation of treatment and prognostic factors of pneumocystis pneumonia in patients with connective tissue diseases.

Ishikawa Y, Nakano K, Tokutsu K, Miyata H, Fujino Y, Matsuda S RMD Open. 2021; 7(1).

PMID: 33688083 PMC: 7944977. DOI: 10.1136/rmdopen-2020-001508.


Reasons for Hospitalization and In-Hospital Mortality in Adult Systemic Lupus Erythematosus.

Manadan A, Kambhatla S, Gauto-Mariotti E, Okoli C, Block J ACR Open Rheumatol. 2020; 2(11):683-689.

PMID: 33164350 PMC: 7672299. DOI: 10.1002/acr2.11195.


The risk of infections in adult patients with systemic lupus erythematosus: systematic review and meta-analysis.

Pego-Reigosa J, Nicholson L, Pooley N, Langham S, Embleton N, Marjenberg Z Rheumatology (Oxford). 2020; 60(1):60-72.

PMID: 33099651 PMC: 7785308. DOI: 10.1093/rheumatology/keaa478.


References
1.
Appel G, Contreras G, Dooley M, Ginzler E, Isenberg D, Jayne D . Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009; 20(5):1103-12. PMC: 2678035. DOI: 10.1681/ASN.2008101028. View

2.
Yale S, Limper A . Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin Proc. 1996; 71(1):5-13. DOI: 10.4065/71.1.5. View

3.
Barber C, Lacaille D, Fortin P . Systematic review of validation studies of the use of administrative data to identify serious infections. Arthritis Care Res (Hoboken). 2013; 65(8):1343-57. DOI: 10.1002/acr.21959. View

4.
Touma Z, Gladman D, Urowitz M, Beyene J, Uleryk E, Shah P . Mycophenolate mofetil for induction treatment of lupus nephritis: a systematic review and metaanalysis. J Rheumatol. 2010; 38(1):69-78. DOI: 10.3899/jrheum.100130. View

5.
Green H, Paul M, Vidal L, Leibovici L . Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc. 2007; 82(9):1052-9. DOI: 10.4065/82.9.1052. View